No Data
No Data
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)
Prime Medicine | 10-K: FY2024 Annual Report
Express News | Prime Medicine FY 2024 GAAP EPS $(1.65) Beats $(1.66) Estimate, Sales $2.983M Beats $929.100K Estimate
Prime Medicine Expects Its Cash, Cash Equivalents and Investments as of Dec 31 Will Be Sufficient to Fund Operating Expenses and Cap Expenditure Requirements Into 1H 2026 >PRME
Prime Medicine FY24 Loss $195.9M >PRME